Literature DB >> 19336593

Epidemiology of sleep apnoea/hypopnoea syndrome and sleep-disordered breathing.

P Jennum1, R L Riha.   

Abstract

Epidemiological studies have revealed a high prevalence of sleep-disordered breathing in the community (up to 20%). A subset of these patients has concurrent symptoms of excessive daytime sleepiness attributable to their nocturnal breathing disorder and is classified as having obstructive sleep apnoea/hypopnoea syndrome (4-5% of the middle-aged population). There is strong evidence for an association of sleep apnoea with cardiovascular and cerebrovascular morbidity, as well as adverse public health consequences. Treatment and diagnosis have remained largely unchanged over the past 25 yrs. In moderate-to-severe obstructive sleep apnoea/hypopnoea syndrome, treatment with continuous positive airway pressure has been shown to be effective. Questions remain as to how to screen patients with sleep-disordered breathing. Should time-consuming diagnostic procedures with high sensitivity and specificity be employed, or should simpler methods be applied for screening populations at risk, e.g. in the primary care sector?

Entities:  

Mesh:

Year:  2009        PMID: 19336593     DOI: 10.1183/09031936.00180108

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  81 in total

1.  Determination of new prediction formula for nasal continuous positive airway pressure in Turkish patients with obstructive sleep apnea syndrome.

Authors:  Ozen K Basoglu; Mehmet Sezai Tasbakan
Journal:  Sleep Breath       Date:  2011-11-12       Impact factor: 2.816

2.  Adherence to continuous positive airway pressure therapy in obstructive sleep apnea syndrome: effect of visual education.

Authors:  Ozen K Basoglu; Meltem Midilli; Rasit Midilli; Cem Bilgen
Journal:  Sleep Breath       Date:  2011-12-14       Impact factor: 2.816

3.  The STOP-Bang equivalent model and prediction of severity of obstructive sleep apnea: relation to polysomnographic measurements of the apnea/hypopnea index.

Authors:  Robert J Farney; Brandon S Walker; Robert M Farney; Gregory L Snow; James M Walker
Journal:  J Clin Sleep Med       Date:  2011-10-15       Impact factor: 4.062

4.  Adherence to APAP in obstructive sleep apnea syndrome: effectiveness of a motivational intervention.

Authors:  Ana Patrícia Teles Dantas; João Carlos Winck; Margarida Figueiredo-Braga
Journal:  Sleep Breath       Date:  2014-07-03       Impact factor: 2.816

5.  Patent foramen ovale closure for patients excluded from the randomized cryptogenic stroke trials: response to letter by Zaman et al.

Authors:  Brunilda Alushi; Alexander Lauten; Ulf Landmesser; Adnan Kastrati
Journal:  Clin Res Cardiol       Date:  2018-06-28       Impact factor: 5.460

Review 6.  Obstructive Sleep Apnea and the Risk of Cognitive Decline in Older Adults.

Authors:  Nadia Gosselin; Andrée-Ann Baril; Ricardo S Osorio; Marta Kaminska; Julie Carrier
Journal:  Am J Respir Crit Care Med       Date:  2019-01-15       Impact factor: 21.405

7.  Morning Diastolic Blood Pressure May Be Independently Associated With Severity of Obstructive Sleep Apnea in Non-Hypertensive Patients: A Cross-Sectional Study.

Authors:  Łukasz Mokros; Wojciech Kuczyński; Łukasz Franczak; Piotr Białasiewicz
Journal:  J Clin Sleep Med       Date:  2017-07-15       Impact factor: 4.062

8.  Use of a level 3 portable monitor for the diagnosis and management of sleep disordered breathing in an inpatient tertiary care setting.

Authors:  Marcus Povitz; R John Kimoff
Journal:  Can Respir J       Date:  2013-11-28       Impact factor: 2.409

Review 9.  Diagnostic approaches to respiratory sleep disorders.

Authors:  Renata L Riha
Journal:  J Thorac Dis       Date:  2015-08       Impact factor: 2.895

Review 10.  Diagnostic accuracy of level 3 portable sleep tests versus level 1 polysomnography for sleep-disordered breathing: a systematic review and meta-analysis.

Authors:  Mohamed El Shayeb; Leigh-Ann Topfer; Tania Stafinski; Lawrence Pawluk; Devidas Menon
Journal:  CMAJ       Date:  2013-11-11       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.